A Registry of AL Amyloidosis (ReAL)

A Registry to Investigate Real-world Natural History, Impact of Therapies and Patterns of Progression of AL Amyloidosis (ReAL)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04839003

Acronym

ReAL

Enrollment

5000

Registered

2021-04-09

Start date

2020-02-27

Completion date

2027-05-01

Last updated

2026-04-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

AL Amyloidosis

Keywords

amyloidosis, prognosis, registry

Brief summary

The purpose of this protocol is to generate a large registry of patients with AL amyloidosis.

Detailed description

Thanks to this registry, it will be possible to collect data at diagnosis and during follow up, in order to be able to describe the natural history of AL amyloidosis in a real-world setting and to define and validate prognostic models, response and relapse criteria applicable at any point of the disease.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 99 Years

Healthy volunteers

Inclusion criteria

1. diagnosis of systemic AL amyloidosis; 2. treatment-naïve (pre-treatment data collected at participating center available for retrospective part); 3. age ≥18 years; 4. ability to understand and willingness to sign an informed consent (patients who already sign informed consent for clinical data to be used in retrospective analyses will be accepted); 5. planned (or ongoing) follow-up at participating center.

Exclusion criteria

1. non-AL amyloidosis; 2. previous treatment for AL amyloidosis.

Design outcomes

Primary

Measure	Time frame
Creation of a registry of patients with AL amyloidosis	5 years

Countries

Italy

Outcome results